Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

01-02-2012 | Epidemiology

Prognostic role of CA15.3 in 7942 patients with operable breast cancer

Authors: M. T. Sandri, M. Salvatici, E. Botteri, R. Passerini, L. Zorzino, N. Rotmensz, A. Luini, C. Mauro, V. Bagnardi, M. C. Cassatella, F. Bottari, C. Casadio, M. Colleoni

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

To assess the prognostic value of presurgical CA15.3 in a large cohort of patients with early breast cancer. A total of 7.942 consecutive patients with breast cancer operated at the European Institute of Oncology between 1998 and 2005 and with presurgical values of CA 15.3 available were included. We explored patterns of recurrence by baseline CA 15.3 values. Mean CA15.3 was 17.0 U/ml. CA15.3 was associated with age, tumor size, nodal involvement, Ki-67 labeling index, grade, HER2 expression, molecular subtype, and perivascular invasion. CA15.3 was independently associated with distant metastases [HR > 20 U/ml vs. ≤ 20 U/ml: 1.34 (95% CI 1.15–1.56)] and death [HR > 20 U/ml vs. ≤ 20 U/ml: 1.30 (95% CI 1.11–1.53)]. When considering CA15.3 as continuous variable, we observed a constant risk of metastasis and death from the lowest values to about 15–20 U/ml, and then a significantly increasing risk with increasing values of CA15.3. Finally, CA15.3 provided significant additional information to the common prognostic factors to predict the occurrence of metastases (C-index P value 0.04). In patients with operable breast cancer, presurgical CA15.3 value is an independent prognostic factor for metastases and deaths. CA15.3 provides additional information to the common prognostic factors and should be considered in the adjuvant therapeutic algorithm.
Literature
1.
go back to reference Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159PubMed Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159PubMed
2.
go back to reference Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 34:197–206PubMedCrossRef Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 34:197–206PubMedCrossRef
3.
go back to reference Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane associated mucin episialian/MUC1. Mol Biol Cell 7:565–577PubMed Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane associated mucin episialian/MUC1. Mol Biol Cell 7:565–577PubMed
4.
go back to reference Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170–1176PubMed Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170–1176PubMed
5.
go back to reference Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1369–1370CrossRef Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1369–1370CrossRef
6.
go back to reference Agrawal B, Gendler SJ, Longenecker BM (1998) The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4:397–403PubMedCrossRef Agrawal B, Gendler SJ, Longenecker BM (1998) The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4:397–403PubMedCrossRef
7.
go back to reference Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201:102–110PubMedCrossRef Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201:102–110PubMedCrossRef
8.
go back to reference Duffy MJ (1999) CA 15–3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579–586PubMed Duffy MJ (1999) CA 15–3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579–586PubMed
9.
go back to reference Duffy MJ, Shering S, Sherry F et al (2000) CA 15–3: a prognostic marker in breast cancer. Int J Biol Markers 15:330–333PubMed Duffy MJ, Shering S, Sherry F et al (2000) CA 15–3: a prognostic marker in breast cancer. Int J Biol Markers 15:330–333PubMed
10.
go back to reference Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef
11.
go back to reference McLaughlin R, McGrath J, Grimes, Given HF (2000) The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 15:340–342PubMed McLaughlin R, McGrath J, Grimes, Given HF (2000) The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 15:340–342PubMed
12.
go back to reference Canizares F, Sola J, Perez M et al (2001) Preoperative values of CA15.3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 22:273–281CrossRef Canizares F, Sola J, Perez M et al (2001) Preoperative values of CA15.3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 22:273–281CrossRef
13.
go back to reference Gion M, Boracchi P, Dittardi R et al (2002) Prognostic role of serum CA 15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181–1188PubMedCrossRef Gion M, Boracchi P, Dittardi R et al (2002) Prognostic role of serum CA 15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181–1188PubMedCrossRef
14.
go back to reference Ebeling FG, Stieber P, Untch M et al (2002) Serum CEA and CA 15–3 as a prognostic factors in primary breast cancer. Br J Cancer 86:1217–1222PubMedCrossRef Ebeling FG, Stieber P, Untch M et al (2002) Serum CEA and CA 15–3 as a prognostic factors in primary breast cancer. Br J Cancer 86:1217–1222PubMedCrossRef
15.
go back to reference Kumpulainen EJ, Keskikuru RJ, Johansson RT (2002) Serum tumor marker CA 15–3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95–102PubMedCrossRef Kumpulainen EJ, Keskikuru RJ, Johansson RT (2002) Serum tumor marker CA 15–3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95–102PubMedCrossRef
16.
go back to reference Molina R, Filella X, Alicarte J et al (2003) Prospective evaluation of CEA and CA15.3 in patients with locoregionale breast cancer. Anticancer Res 23:1035–1042PubMed Molina R, Filella X, Alicarte J et al (2003) Prospective evaluation of CEA and CA15.3 in patients with locoregionale breast cancer. Anticancer Res 23:1035–1042PubMed
17.
go back to reference Duffy MJ, Duggan C, Keane R et al (2004) High preoperative CA 15–3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559–563PubMedCrossRef Duffy MJ, Duggan C, Keane R et al (2004) High preoperative CA 15–3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559–563PubMedCrossRef
18.
go back to reference Martin A, Corte MD, Alvarez AM et al (2006) Prognostic value of pre-operative serum CA15.3 levels in breast cancer. Anticancer Res 26:3965–3972PubMed Martin A, Corte MD, Alvarez AM et al (2006) Prognostic value of pre-operative serum CA15.3 levels in breast cancer. Anticancer Res 26:3965–3972PubMed
19.
go back to reference Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008) Does the pre-operative value of serum CA15.3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9:445–448PubMed Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008) Does the pre-operative value of serum CA15.3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9:445–448PubMed
20.
go back to reference Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann of Oncol 19:675–681CrossRef Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann of Oncol 19:675–681CrossRef
21.
go back to reference Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRef Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRef
22.
go back to reference Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef
23.
go back to reference Viale G, Regan MM, Maiorano E et al (2007) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. J Clin Oncol 25:3846–3852PubMedCrossRef Viale G, Regan MM, Maiorano E et al (2007) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. J Clin Oncol 25:3846–3852PubMedCrossRef
24.
go back to reference Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575PubMedCrossRef Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575PubMedCrossRef
25.
go back to reference Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMedCrossRef Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMedCrossRef
26.
go back to reference Gray RJ (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141–1154CrossRef Gray RJ (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141–1154CrossRef
27.
28.
go back to reference Antolini L, Nam B-H, D’Agostino RB (2004) Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 33:2117–2135CrossRef Antolini L, Nam B-H, D’Agostino RB (2004) Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 33:2117–2135CrossRef
29.
go back to reference Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef
30.
go back to reference Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257–259PubMedCrossRef Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257–259PubMedCrossRef
31.
go back to reference Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef
32.
go back to reference Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038PubMedCrossRef Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038PubMedCrossRef
33.
go back to reference Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224–240PubMed Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224–240PubMed
34.
go back to reference Perou C, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou C, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
35.
go back to reference Sorlie T, Perou AM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef Sorlie T, Perou AM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef
36.
go back to reference Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef
37.
go back to reference Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317–328PubMedCrossRef Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317–328PubMedCrossRef
Metadata
Title
Prognostic role of CA15.3 in 7942 patients with operable breast cancer
Authors
M. T. Sandri
M. Salvatici
E. Botteri
R. Passerini
L. Zorzino
N. Rotmensz
A. Luini
C. Mauro
V. Bagnardi
M. C. Cassatella
F. Bottari
C. Casadio
M. Colleoni
Publication date
01-02-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1863-x

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine